Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05229809
Other study ID # CI2021A01802
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 1, 2022
Est. completion date July 31, 2024

Study information

Verified date October 2022
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact Guanghui Zhu, Doctor
Phone +86 13315714979
Email zhugh0822@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Yiqi Wenyang Jiedu prescription for postoperative gastric cancer.


Description:

This study include a multicenter, randomized, double-blind, placebo, parallel controlled clinical trial.The randomized clinical trial will enroll approximately 212 patients. Participants will be randomly divided into experimental (n=106) and control groups (n=106).Patients in the experimental group was treated with Yiqiuyang Jiedu prescription within 6-8 months after radical gastroctomy and after the completion of standard regimen (XELOX and SOX) for at least 6 cycles of adjuvant chemotherapy. Patients in the control group will receive the placebo.The primary endpoint is 2-year DFS (Disease-free survival) rate after surgery, that refers to the proportion of patients who do not have recurrence, metastasis or death (from any cause) within 2 years after surgery. The research protocol was approved by the relevant ethics committees, and the study was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines. Patients gave written informed consent to participate in the trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 212
Est. completion date July 31, 2024
Est. primary completion date July 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. The non-esophagogastric junction gastric cancer of stage II-III that met the diagnostic criteria, and no tumor recurrence and metastasis was determined by imaging; 2. Within 6-8 months after radical gastrectomy for gastric cancer (R0), adjuvant chemotherapy of standard regimen (XELOX and SOX) has been completed for at least 6 cycles; 3. ECOG score 0-2; 4. 18-75 years old, male or female; 5. The expected survival time is =3 months; 6. Voluntary participation in the study, signing informed consent, good compliance with follow-up. Exclusion Criteria: 1. Patients with other primary tumors; 2. Gastric cancer patients were pathologically diagnosed as adenosquamous carcinoma, with lymphoid stromal carcinoma (medullary carcinoma), hepatoid adenocarcinoma, squamous cell carcinoma, signed-ring cell carcinoma, undifferentiated carcinoma, gastric neuroendocrine tumor, gastric mesenchymal tumor, gastric malignant lymphoma and other gastric malignancies; 3. Patients who had previously received preoperative neoadjuvant chemotherapy; 4. Patients with past or current targeted drug therapy; 5. Patients undergoing previous or ongoing gastric radiotherapy; 6. Patients with past or ongoing tumor immunotherapy; 7. Mental patients; 8. Patients with serious and uncontrolled organic diseases or infections, such as decompensated heart, lung and renal failure, which lead to intolerance of chemotherapy; 9. Patients who received clinical trials of small molecule drugs within 28 days or large molecule drugs within 3 months; 10. Patients who are known to be allergic or intolerant to the study drug.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Yiqi Wenyang Jiedu prescription
The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
Simulation agent of Yiqi Wenyang Jiedu prescription
It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.

Locations

Country Name City State
China Cancer Hospital, Chinese Academy of Medical Sciences Beijing Beijing
China Wangjing Hospital, China Academy of Chinese Medical Sciences Beijing Beijing
China Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing Beijing
China The First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou Guangdong
China Jiangsu Hospital of Traditional Chinese Medicine Nanjing Jiangsu
China Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Jie Li

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 2-year disease-free survival rate Refers to the proportion of patients who did not experience recurrence, metastasis or death (from any cause) within 2 years after surgery. The day of surgery until the second year.
Secondary Disease-free survival It is the time from randomization to tumor progression or death (from any cause). Randomization until disease recurrence, metastasis, death (from any cause) , or 36 months after surgery, whichever occurs first.
Secondary Overall survival It is the time from randomization to death (from any cause). Randomization until death (from any cause) or 36 months after surgery, whichever occurs first.
Secondary Cumulative annual recurrence and metastasis rate for 1-3 years Refers to the proportion of patients with recurrence and metastasis within 1-3 years from the day of surgery. The day of surgery until the once, second and third year.
Secondary Cumulative annual survival rate for 1-3 years Refers to the proportion of patients with survical within 1-3 years from the day of surgery. The day of surgery until the once, second and third year.
Secondary Indexes related to fat distribution Total Fat Area, Visceral Fat Area and Subcutaneous Fat Area. They measure fat area on cross-sectional images using plain CT scanning. before and after every third cycles of treatment (each cycle is 28 days), assessed up to recurrence and metastasis (up to 3 years after surgery).
Secondary Visceral Adiposity Index It is a new assessment of visceral fat based on waist circumference (WC), BMI, triglyceride (TG) and HDL.
Male VAI = during [WC/(39.68 + 1.88 x BMI)] * (TG / 1.03) * (1.31 / HDL). Female VAI = during [WC/(36.58 + 1.89 x BMI)] * (TG / 0.81) * (1.52 / HDL).
before and after every third cycles of treatment (each cycle is 28 days), assessed up to recurrence and metastasis (up to 3 years after surgery).
Secondary Tumor marker CEA, CA724 and CA199 before and after every third cycles of treatment (each cycle is 28 days), assessed up to recurrence and metastasis (up to 3 years after surgery).
Secondary Peripheral blood inflammatory index The ratio of lymphocytes to monocytes (LMR) and ratio of Lymphocyte to neutrophil ratio (LNR) before and after every third cycles of treatment (each cycle is 28 days), assessed up to recurrence and metastasis (up to 3 years after surgery).
Secondary Prognostic nutritional index Serum albumin level (g/L) +5× total number of peripheral blood lymphocytes (×10 ^ 9 /L) before and after every third cycles of treatment (each cycle is 28 days), assessed up to recurrence and metastasis (up to 3 years after surgery).
Secondary Quality of life of the patient This will be measured with Quality of Life Questionnaire of Stomach22 (QLQ-STO22). The minimum score is 22 and the maximum is 88. A higher score indicates a poorer quality of life. Before and after every cycle of treatment (each cycle is 28 days), assessed up to death or 3 years after surgery.
Secondary Evaluation of the patient's symptoms This will be measured with M. D. Anderson Symptom Inventory (MDASI-GI) and Postgastrectomy Syndrome Assessment Scale (PGSAS-45). The minimum score of MDASI-GI is 0 and the maximum is 240. The minimum score of PGSAS-45 is 0 and the maximum is 271. A higher score indicates a poorer symptom. Before and after every cycle of treatment (each cycle is 28 days), assessed up to death or 3 years after surgery.
Secondary Medication compliance The number of cases and percentage were calculated as < 80%, 80-120% and > 120% From randomization to the end of the sixth course of medication (up to 24 weeks).
Secondary Percentage of Participants With Adverse Events Percentage of Participants With Adverse Events in different arms. Baseline until disease progression, death, or assessed up to 36 months after surgery.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Not yet recruiting NCT03599778 - XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma Phase 1/Phase 2
Terminated NCT00256321 - Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma Phase 2
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Recruiting NCT02617134 - CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Phase 1/Phase 2
Recruiting NCT02317471 - Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96 Phase 1/Phase 2
Active, not recruiting NCT03735511 - A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Recruiting NCT05596188 - Anxiety Before Non-cardiac Surgery in Adults
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Terminated NCT04254107 - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Phase 1
Recruiting NCT01348009 - Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer Phase 1/Phase 2
Recruiting NCT00639522 - Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma Phase 1
Recruiting NCT05811546 - Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma
Recruiting NCT02409199 - A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer Phase 2/Phase 3
Completed NCT00970138 - Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer Phase 2/Phase 3
Recruiting NCT06408220 - Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer N/A
Recruiting NCT04443036 - Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma N/A
Active, not recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Recruiting NCT02839954 - CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor Phase 1/Phase 2